ArriVent BioPharma (AVBP) reported a trend toward improvement in overall survival in its clinical data, though the data are not yet mature. This follows earlier reports of clinical benefit in secondary endpoints including progression-free survival and objective response rate.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
